Skip to content
StockMarketAgent
Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0IIM stock hub

LON/0IIM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

LON/0IIMis not in this month’s coverageGet our monthly research letter — no spam
Fair value midpoint
n/a
Fair value pending
Upside to midpoint
n/a
Based on latest report
Confidence
n/a
Data quality and model convergence
Market cap
593.2M
London Stock Exchange
Market data

Live price

Current market quote for this ticker.

Current price
LON/0IIM
In the news

Latest news · LON/0IIM

Recent company headlines from major financial publishers.

Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Loading
—
Fetching the latest headlines.
Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming
DateLoading
Window—
EPS estimate—
Revenue estimate—
Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E23.7
P25 12.9P50 16.9P75 23.5
Trailing P/En/a
P25 15.9P50 22.9P75 35.8
ROEn/a
P25 -54.2P50 2.1P75 13.7
ROIC23.5
P25 -38.1P50 3.3P75 11.9
Benchmarks - 1M
S&P 500n/a
Nasdaq Compositen/a
Dow Jones Industrial Averagen/a
Russell 2000n/a
Indicator catalog

All LON/0IIM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields
177
Groups with data
11
Currency
USD
Showing 177 of 177 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

20
MetricValue
Country
United States
Country code
UK
Employees
294
Employees Change
64%
Employees Change Percent
26.67
Enterprise value
$877.6M
Exchange
London Stock Exchange
Financial currency
USD
First seen
2026-05-10
Industry
Medical - Pharmaceuticals
Isin
US29664W1053
Last refreshed
2026-05-10
Market cap
$593.2M
Price
$3.14
Price currency
USD
Rev Per Employee
1,077,341.06x
Sector
Healthcare
Sic
2834
Symbol
lon/0IIM
Website
https://www.esperion.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

10
MetricValue
Earnings Yield
-0.95%
EV Earnings
-156.12x
EV/EBIT
15.78x
EV/EBITDA
15.24x
EV/FCF
-63.07x
EV/Sales
2.86x
FCF yield
-2.35%
Forward P/E
23.71x
P/B ratio
-2.54x
P/S ratio
1.87x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

17
MetricValue
EBIT Margin
18.12%
EBITDA Margin
18.15%
Gross margin
56.94%
Gross Profit
$180.3M
Gross Profit Growth
74.23%
Gross Profit Growth Q
117.85%
Gross Profit Growth5 Y
21.66%
Net Income
$-5.6M
Net Income Growth Quarters
2%
Net Income Growth Years
4%
Pretax Margin
-1.33%
Profit Margin
-1.77%
Profit Per Employee
$-19,121
ROA
12.04
Roa5y
-18.63
ROCE
46.73
ROIC
23.47

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

11
MetricValue
Cagr1y
261.24%
Cagr3y
31.14%
Cagr5y
-32.04%
EPS Growth Quarters
2
EPS Growth Years
4
Revenue Growth
61.13x
Revenue Growth Q
23.25x
Revenue Growth Quarters
4x
Revenue Growth Years
3x
Revenue Growth3 Y
72.86x
Revenue Growth5 Y
12.35x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

19
MetricValue
Asset Turnover
$1.06
Assets
$350.3M
Cash
$118.3M
Current Assets
$337M
Current Liabilities
$220.3M
Debt
$411.8M
Debt EBITDA
$6.93
Debt FCF
$-29.59
Equity
$-233.2M
Interest Coverage
0.89
Liabilities
$583.5M
Long Term Assets
$13.3M
Long Term Liabilities
$363.2M
Net Cash
$-293.6M
Net Cash By Market Cap
$-49.49
Net Debt EBITDA
$5.11
Tangible Book Value
$-233.2M
Tangible Book Value Per Share
$-0.91
WACC
11.37

Liquidity

Current-asset coverage and working-capital efficiency metrics.

6
MetricValue
Current ratio
1.53
Inventory Turnover
1.39
Net Working Capital
$64.7M
Quick ratio
0.96
Working Capital
$120.5M
Working Capital Turnover
$3.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

1
MetricValue
Buyback Yield
-14.32%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

35
MetricValue
1Y total return
260.92%
200-day SMA
2.82
3Y total return
125.58%
50-day SMA
2.55
50-day SMA vs 200-day SMA
50under200
5Y total return
-85.5%
All Time High
34.48
All Time High Change
-90.89%
All Time High Date
2021-02-08
All Time Low
0.7
All Time Low Change
348.57%
All Time Low Date
2025-05-15
ATR
0.17
Beta
0.91
Ch YTD
-15.82
High
3.15
High52
4.17
High52 Date
2026-01-08
High52ch
-24.7%
Low
3.14
Low52
0.7
Low52 Date
2025-05-15
Low52ch
348.57%
Ma50ch
23.09%
Price vs 200-day SMA
11.35%
RSI
71.13
RSI Monthly
50.48
RSI Weekly
54.19
Sharpe ratio
1.51x
Sortino ratio
2.92
Total Return
-14.32%
Tr YTD
-15.82
Tr1m
41.12%
Tr1w
0.64%
Tr3m
-7.93%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

2
MetricValue
Operating Income
$57.4M
Operating margin
18.12

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

6
MetricValue
Float
255,155,376%
Net Borrowing
-40,278,720.8
Shares Insiders
0.87%
Shares Institutions
63.96%
Shares Qo Q
-11.67%
Shares Yo Y
14.32%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

50
MetricValue
Adjusted FCF
$-21.4M
Average Volume
93,542.9x
Bv Per Share
-0.91
CAPEX
$-143,131
Ch1m
41.12
Ch1w
0.64
Ch1y
260.9
Ch3m
-7.94
Ch3y
125.6
Ch5y
-85.5
Ch6m
23.14
Change
-0.02%
Change From Open
0
Close
3.14
Days Gap
-0.03
Depreciation Amortization
77,752.5
Dollar Volume
7,708.7
Earnings Date
2026-05-07
EBIT
$57.4M
EBITDA
$57.5M
EPS
$-0.03
F Score
5
FCF
$-13.9M
FCF EV Yield
-1.59x
Financing CF
45,363,327
Fiscal Year End
December
Founded
2,008
Income Tax
$1.4M
Investing CF
-143,131
Is Primary Listing
0
Last Earnings Date
2026-05-07
Last Report Date
2026-03-31
Ma150
3.05
Ma150ch
2.98%
Ma20
2.34
Ma20ch
34.3%
Net CF
31,447,090
Next Earnings Date
2026-08-04
Open
3.14
Position In Range
33.33
Ppne
2,209,344.2
Price Date
2026-05-08
Price EBITDA
$10.32
Relative Volume
0.03x
Revenue
316,738,272x
SBC By Revenue
2.37x
Share Based Comp
7,502,621
Tax By Revenue
0.44x
Tr6m
23.14%
Volume
2,455
Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate
n/a
Named kill scenarios are reviewed before any bullish rating can stand.
Moat score
n/a
Business quality stays separate from stock attractiveness.
Forward P/E
n/a
Valuation uses the full report model stack, not a single multiple.
Next action
Research pending
Final action steps are kept in the recommendation tab.
Income

Does LON/0IIM pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0IIM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

1Y total return
+260.9%
S&P 500 1Y: n/a
3Y total return
+125.6%
S&P 500 3Y: n/a
5Y total return
-85.5%
S&P 500 5Y: n/a
10Y total return
n/a
S&P 500 10Y: n/a
Ownership

Who owns LON/0IIM?

Insider, institutional, and short-interest positioning.

Institutional ownership
+64.0%
Share of float held by funds and institutions
Insider ownership
+0.9%
Stake held by company insiders. Higher generally signals alignment.
Short interest
n/a
Float sold short by bearish positioning
Y/Y dilution
+14.3%
Negative means the company is buying back shares.
Technical

LON/0IIM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)
71.1
Above 70: short-term overbought
Price vs 200-day MA
+11.3%
50/200-day relationship not available
Beta (5Y)
0.91
Moves roughly with the market
Sharpe ratio
1.51
Risk-adjusted return — higher is better; >1.0 is solid.
Questions

About LON/0IIM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0IIM stock rating?

lon/0IIM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0IIM analysis?

The full report lives at /stocks/lon/0IIM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0IIM?

The latest report frames lon/0IIM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0IIM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.